Comparison of artesunate and quinine in the treatment of severe falciparum malaria: a randomized control trial

Manish B. Nandeshwar; Ujwala P. Gawali; Amit A. Bansode

doi:10.18203/2319-2003.ijbcp20150389

Authors

Manish B. Nandeshwar Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India
Ujwala P. Gawali Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India,
Amit A. Bansode Tata Consultancy Services, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150389

Keywords:

Malaria, Artemisinin, Quinine

Abstract

Background: Severe malaria is a medical emergency that required prompt clinical assessment and management. Very few studies underwent to evaluate the best possible treatment for severe malaria.

Methods: This is a prospective, randomized, open-labeled, study to evaluate the efficacy and safety of artesunate compared with quinine. Totally, 50 patients were included in each group. Patients above 18 years, peripheral smear positive and fulfilling the WHO criteria were included. The endpoint of the study was fever clearance time (FCT), parasite clearance time (PCT) and coma resolution time (CRT), and the adverse effect if any were compared for safety analysis.

Results: FCT and PCT were much less with artesunate (29.64 and 39.72 hrs) as compared to quinine (51.12 and 55.20 hrs). CRT was less with quinine (25.80 hrs) than artesunate (42 hrs). The incidence of adverse effects such as hypoglycemia and QT prolongation are significant with quinine compared to artesunate.

Conclusions: Artesunate is a better alternative for severe malaria with minimal side effects.

Metrics

Metrics Loading ...

References

Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo Z, editors. Harrison’s, Principles of Internal Medicine. 18th Edition. New York: McGraw Hill; 2012: 1688-705.

Sinclair D, Donegan S, Lalloo D.G, Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2011;(3):CD005967.

Day N, Dondorp AM. The management of patients with severe malaria. Am J Trop Med Hyg. 2007;77 6 Suppl:29-35.

Newton PN, Angus BJ, Chierakul W, Dondorp A, Ruangveerayuth R, Silamut K, et al. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37(1):7-16.

Tran TH, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335(2):76-83.

Kyu HH, Fernández E. Artemisinin derivatives versus quinine for cerebral malaria in African children: a systematic review. Bull World Health Organ. 2009;87:896-904.

Mohanty AK, Rath BK, Mohanty R, Samal AK, Mishra K. Randomized control trial of quinine and artesunate in complicated malaria. Indian J Pediatr 2004;71(4):291-5.

Patel D, Sadatia V, Patel M. Treatment of severe falciparum malaria: quinine versus artesunate. Int J Basic Clin Pharmacol. 2013;2(1):30-6.

Valecha N, Tripathi KD. Artemisinin: current status in malaria. Indian J Pharmacol. 1997;29:71-5.

Li Q, Weina P. Artesunate: the best drug in the treatment of severe and complicated malaria: review. Pharmaceuticals. 2010;3(7):2322-32.

Haroon N, Amichandwala K, Mahesah GS. Comparative efficacy of quinine and artesunate in the treatment of severe malaria: a randomized controlled trial. JK Sci. 2005;7(1):1-4.